<?xml version="1.0" encoding="UTF-8"?>
<document id="DrugDDI.d123" origId="Betaxolol"><sentence id="DrugDDI.d123.s0" origId="s0" text="The following drugs have been coadministered with Kerlone and have not altered its pharmacokinetics: cimetidine, nifedipine, chlorthalidone, and hydrochlorothiazide."><entity id="DrugDDI.d123.s0.e0" origId="s0.p0" charOffset="14-19" type="drug" text="drugs"/><entity id="DrugDDI.d123.s0.e1" origId="s0.p4" charOffset="50-57" type="drug" text="Kerlone"/><entity id="DrugDDI.d123.s0.e2" origId="s0.p11" charOffset="101-111" type="drug" text="cimetidine"/><entity id="DrugDDI.d123.s0.e3" origId="s0.p12" charOffset="113-123" type="drug" text="nifedipine"/><entity id="DrugDDI.d123.s0.e4" origId="s0.p13" charOffset="125-139" type="drug" text="chlorthalidone"/><entity id="DrugDDI.d123.s0.e5" origId="s0.p15" charOffset="145-164" type="drug" text="hydrochlorothiazide"/><pair id="DrugDDI.d123.s0.p0" e1="DrugDDI.d123.s0.e0" e2="DrugDDI.d123.s0.e1" interaction="false"/><pair id="DrugDDI.d123.s0.p1" e1="DrugDDI.d123.s0.e0" e2="DrugDDI.d123.s0.e2" interaction="false"/><pair id="DrugDDI.d123.s0.p2" e1="DrugDDI.d123.s0.e0" e2="DrugDDI.d123.s0.e3" interaction="false"/><pair id="DrugDDI.d123.s0.p3" e1="DrugDDI.d123.s0.e0" e2="DrugDDI.d123.s0.e4" interaction="false"/><pair id="DrugDDI.d123.s0.p4" e1="DrugDDI.d123.s0.e0" e2="DrugDDI.d123.s0.e5" interaction="false"/><pair id="DrugDDI.d123.s0.p5" e1="DrugDDI.d123.s0.e1" e2="DrugDDI.d123.s0.e2" interaction="false"/><pair id="DrugDDI.d123.s0.p6" e1="DrugDDI.d123.s0.e1" e2="DrugDDI.d123.s0.e3" interaction="false"/><pair id="DrugDDI.d123.s0.p7" e1="DrugDDI.d123.s0.e1" e2="DrugDDI.d123.s0.e4" interaction="false"/><pair id="DrugDDI.d123.s0.p8" e1="DrugDDI.d123.s0.e1" e2="DrugDDI.d123.s0.e5" interaction="false"/><pair id="DrugDDI.d123.s0.p9" e1="DrugDDI.d123.s0.e2" e2="DrugDDI.d123.s0.e3" interaction="false"/><pair id="DrugDDI.d123.s0.p10" e1="DrugDDI.d123.s0.e2" e2="DrugDDI.d123.s0.e4" interaction="false"/><pair id="DrugDDI.d123.s0.p11" e1="DrugDDI.d123.s0.e2" e2="DrugDDI.d123.s0.e5" interaction="false"/><pair id="DrugDDI.d123.s0.p12" e1="DrugDDI.d123.s0.e3" e2="DrugDDI.d123.s0.e4" interaction="false"/><pair id="DrugDDI.d123.s0.p13" e1="DrugDDI.d123.s0.e3" e2="DrugDDI.d123.s0.e5" interaction="false"/><pair id="DrugDDI.d123.s0.p14" e1="DrugDDI.d123.s0.e4" e2="DrugDDI.d123.s0.e5" interaction="false"/></sentence><sentence id="DrugDDI.d123.s1" origId="s1" text="Concomitant administration of Kerlone with the oral anticoagulant warfarin has been shown not to potentiate the anticoagulant effect of warfarin."><entity id="DrugDDI.d123.s1.e0" origId="s1.p17" charOffset="30-37" type="drug" text="Kerlone"/><entity id="DrugDDI.d123.s1.e1" origId="s1.p18" charOffset="47-75" type="drug" text="oral anticoagulant warfarin"/><entity id="DrugDDI.d123.s1.e2" origId="s1.p25" charOffset="136-144" type="drug" text="warfarin"/><pair id="DrugDDI.d123.s1.p0" e1="DrugDDI.d123.s1.e0" e2="DrugDDI.d123.s1.e1" interaction="false"/><pair id="DrugDDI.d123.s1.p1" e1="DrugDDI.d123.s1.e0" e2="DrugDDI.d123.s1.e2" interaction="false"/><pair id="DrugDDI.d123.s1.p2" e1="DrugDDI.d123.s1.e1" e2="DrugDDI.d123.s1.e2" interaction="false"/></sentence><sentence id="DrugDDI.d123.s2" origId="s2" text="Catecholamine-depleting drugs (e.g., reserpine) may have an additive effect when given with beta-blocking agents."><entity id="DrugDDI.d123.s2.e0" origId="s2.p26" charOffset="24-29" type="drug" text="drugs"/><entity id="DrugDDI.d123.s2.e1" origId="s2.p29" charOffset="37-46" type="drug" text="reserpine"/><entity id="DrugDDI.d123.s2.e2" origId="s2.p36" charOffset="92-111" type="drug" text="beta-blocking agent"/><pair id="DrugDDI.d123.s2.p0" e1="DrugDDI.d123.s2.e0" e2="DrugDDI.d123.s2.e1" interaction="false"/><pair id="DrugDDI.d123.s2.p1" e1="DrugDDI.d123.s2.e0" e2="DrugDDI.d123.s2.e2" interaction="true"/><pair id="DrugDDI.d123.s2.p2" e1="DrugDDI.d123.s2.e1" e2="DrugDDI.d123.s2.e2" interaction="false"/></sentence><sentence id="DrugDDI.d123.s3" origId="s3" text="Patients treated with a beta-adrenergic receptor blocking agent plus a catecholamine depletor should therefore be closely observed for evidence of hypotension or marked bradycardia, which may produce vertigo, syncope, or postural hypotension."><entity id="DrugDDI.d123.s3.e0" origId="s3.p39" charOffset="24-63" type="drug" text="beta-adrenergic receptor blocking agent"/></sentence><sentence id="DrugDDI.d123.s4" origId="s4" text="Should it be decided to discontinue therapy in patients receiving beta-blockers and clonidine concurrently, the beta-blocker should be discontinued slowly over several days before the gradual withdrawal of clonidine."><entity id="DrugDDI.d123.s4.e0" origId="s4.p66" charOffset="66-80" type="drug" text="beta-blockers"/><entity id="DrugDDI.d123.s4.e1" origId="s4.p68" charOffset="84-93" type="drug" text="clonidine"/><entity id="DrugDDI.d123.s4.e2" origId="s4.p69" charOffset="112-124" type="drug" text="beta-blocker"/><entity id="DrugDDI.d123.s4.e3" origId="s4.p75" charOffset="206-215" type="drug" text="clonidine"/><pair id="DrugDDI.d123.s4.p0" e1="DrugDDI.d123.s4.e0" e2="DrugDDI.d123.s4.e1" interaction="true"/><pair id="DrugDDI.d123.s4.p1" e1="DrugDDI.d123.s4.e0" e2="DrugDDI.d123.s4.e2" interaction="false"/><pair id="DrugDDI.d123.s4.p2" e1="DrugDDI.d123.s4.e0" e2="DrugDDI.d123.s4.e3" interaction="false"/><pair id="DrugDDI.d123.s4.p3" e1="DrugDDI.d123.s4.e1" e2="DrugDDI.d123.s4.e2" interaction="false"/><pair id="DrugDDI.d123.s4.p4" e1="DrugDDI.d123.s4.e1" e2="DrugDDI.d123.s4.e3" interaction="false"/><pair id="DrugDDI.d123.s4.p5" e1="DrugDDI.d123.s4.e2" e2="DrugDDI.d123.s4.e3" interaction="false"/></sentence><sentence id="DrugDDI.d123.s5" origId="s5" text="Literature reports suggest that oral calcium antagonists may be used in combination with beta-adrenergic blocking agents when heart function is normal, but should be avoided in patients with impaired cardiac function."><entity id="DrugDDI.d123.s5.e0" origId="s5.p78" charOffset="37-55" type="drug" text="calcium antagonist"/><entity id="DrugDDI.d123.s5.e1" origId="s5.p83" charOffset="89-120" type="drug" text="beta-adrenergic blocking agents"/><pair id="DrugDDI.d123.s5.p0" e1="DrugDDI.d123.s5.e0" e2="DrugDDI.d123.s5.e1" interaction="false"/></sentence><sentence id="DrugDDI.d123.s6" origId="s6" text="Hypotension, AV conduction disturbances, and left ventricular failure have been reported in some patients receiving beta-adrenergic blocking agents when an oral calcium antagonist was added to the treatment regimen."><entity id="DrugDDI.d123.s6.e0" origId="s6.p103" charOffset="116-147" type="drug" text="beta-adrenergic blocking agents"/><entity id="DrugDDI.d123.s6.e1" origId="s6.p105" charOffset="161-179" type="drug" text="calcium antagonist"/><pair id="DrugDDI.d123.s6.p0" e1="DrugDDI.d123.s6.e0" e2="DrugDDI.d123.s6.e1" interaction="true"/></sentence><sentence id="DrugDDI.d123.s7" origId="s7" text="Hypotension was more likely to occur if the calcium antagonist were a dihydropyridine derivative, e.g., nifedipine, while left ventricular failure and AV conduction disturbances, including complete heart block, were more likely to occur with either verapamil or diltiazem."><entity id="DrugDDI.d123.s7.e0" origId="s7.p113" charOffset="44-62" type="drug" text="calcium antagonist"/><entity id="DrugDDI.d123.s7.e1" origId="s7.p115" charOffset="70-85" type="drug" text="dihydropyridine"/><entity id="DrugDDI.d123.s7.e2" origId="s7.p118" charOffset="104-114" type="drug" text="nifedipine"/><entity id="DrugDDI.d123.s7.e3" origId="s7.p130" charOffset="249-258" type="drug" text="verapamil"/><entity id="DrugDDI.d123.s7.e4" origId="s7.p132" charOffset="262-271" type="drug" text="diltiazem"/><pair id="DrugDDI.d123.s7.p0" e1="DrugDDI.d123.s7.e0" e2="DrugDDI.d123.s7.e1" interaction="false"/><pair id="DrugDDI.d123.s7.p1" e1="DrugDDI.d123.s7.e0" e2="DrugDDI.d123.s7.e2" interaction="false"/><pair id="DrugDDI.d123.s7.p2" e1="DrugDDI.d123.s7.e0" e2="DrugDDI.d123.s7.e3" interaction="false"/><pair id="DrugDDI.d123.s7.p3" e1="DrugDDI.d123.s7.e0" e2="DrugDDI.d123.s7.e4" interaction="false"/><pair id="DrugDDI.d123.s7.p4" e1="DrugDDI.d123.s7.e1" e2="DrugDDI.d123.s7.e2" interaction="false"/><pair id="DrugDDI.d123.s7.p5" e1="DrugDDI.d123.s7.e1" e2="DrugDDI.d123.s7.e3" interaction="false"/><pair id="DrugDDI.d123.s7.p6" e1="DrugDDI.d123.s7.e1" e2="DrugDDI.d123.s7.e4" interaction="false"/><pair id="DrugDDI.d123.s7.p7" e1="DrugDDI.d123.s7.e2" e2="DrugDDI.d123.s7.e3" interaction="false"/><pair id="DrugDDI.d123.s7.p8" e1="DrugDDI.d123.s7.e2" e2="DrugDDI.d123.s7.e4" interaction="false"/><pair id="DrugDDI.d123.s7.p9" e1="DrugDDI.d123.s7.e3" e2="DrugDDI.d123.s7.e4" interaction="false"/></sentence><sentence id="DrugDDI.d123.s8" origId="s8" text="Risk of Anaphylactic Reaction: Although it is known that patients on beta-blockers may be refractory to epinephrine in the treatment of anaphylactic shock, beta-blockers can, in addition, interfere with the modulation of allergic reaction and lead to an increased severity and/or frequency of attacks."><entity id="DrugDDI.d123.s8.e0" origId="s8.p141" charOffset="69-83" type="drug" text="beta-blockers"/><entity id="DrugDDI.d123.s8.e1" origId="s8.p145" charOffset="104-115" type="drug" text="epinephrine"/><entity id="DrugDDI.d123.s8.e2" origId="s8.p148" charOffset="156-170" type="drug" text="beta-blockers"/><pair id="DrugDDI.d123.s8.p0" e1="DrugDDI.d123.s8.e0" e2="DrugDDI.d123.s8.e1" interaction="false"/><pair id="DrugDDI.d123.s8.p1" e1="DrugDDI.d123.s8.e0" e2="DrugDDI.d123.s8.e2" interaction="false"/><pair id="DrugDDI.d123.s8.p2" e1="DrugDDI.d123.s8.e1" e2="DrugDDI.d123.s8.e2" interaction="false"/></sentence><sentence id="DrugDDI.d123.s9" origId="s9" text="Severe allergic reactions including anaphylaxis have been reported in patients exposed to a variety of allergens either by repeated challenge, or accidental contact, and with diagnostic or therapeutic agents while receiving beta-blockers."><entity id="DrugDDI.d123.s9.e0" origId="s9.p178" charOffset="189-207" type="drug" text="therapeutic agents"/><entity id="DrugDDI.d123.s9.e1" origId="s9.p180" charOffset="224-238" type="drug" text="beta-blockers"/><pair id="DrugDDI.d123.s9.p0" e1="DrugDDI.d123.s9.e0" e2="DrugDDI.d123.s9.e1" interaction="false"/></sentence><sentence id="DrugDDI.d123.s10" origId="s10" text="Such patients may be unresponsive to the usual doses of epinephrine used to treat allergic reaction."><entity id="DrugDDI.d123.s10.e0" origId="s10.p186" charOffset="56-67" type="drug" text="epinephrine"/></sentence></document>